As a domestically developed cell therapy has passed a major review for health insurance coverage, expectations for commercialization among the developers are on the rise. This therapy targets patients with hematologic cancers who experience recurrence or do not respond to existing anticancer treatments. Since it can be manufactured and supplied through local production facilities, health insurance reimbursement is expected to help reduce treatment costs for patients and improve accessibility to regional medical institutions if implemented.


Investors are paying close attention to whether passing this review will lead to actual sales growth and a reevaluation of corporate value. However, they should note that final reimbursement listing still requires drug price negotiations and additional approval steps, making it important to check the timeline and specific conditions. When reviewing investment opportunities as reimbursement and the expansion of treatment centers become more concrete, it will be necessary to manage funds by considering both additional investment capacity and repayment plans.


HighStockLoan has maintained its number one position in the industry for 22 years, operating a variety of stock financing products, including those with an annual interest rate in the 5% range. It can be used not only to raise new investment funds but also for the management of funds through refinancing of credit or margin transactions, attracting attention as an option for investors wishing to respond flexibly to market volatility.

Progress in Reimbursement Review for Domestic Cell Therapy...How to Maximize Investment Opportunities Up to Fourfold View original image

[Go to HighStockLoan, No. 1 in the industry: https://www.hisl.co.kr]


◆ HighStockLoan: Lowest Industry Interest Rate in the 5% Range per Year for Additional Investments and Credit/Margin Refinancing!

HighStockLoan has launched a securities-based credit product at a lowest-in-the-industry interest rate in the 5% range per year so that any investor can experience stock-backed loans with ease. You can use it not only for stock purchases but also for both margin and credit refinancing at securities firms, and it is available up to four times your own capital with no distinctions by credit rating. Investors using the alternative trading system (NXT) can also take advantage of it.


For investors interested in HighStockLoan’s diverse customized products, you can contact the customer service center (☎1566-5113) at any time, 24/7, and speak to a professional consultant conveniently regardless of loan eligibility.


○ Newly released product with the lowest industry rate in the 5% range annually

○ ETF trading available

○ Number one in market share for 22 consecutive years, winner of Korea’s First Brand Award for 17 consecutive years

○ Real-time repayment of margin/credit at securities firms

○ Alternative Trading System (NXT) trading available

○ Reliable consulting quality assurance program

* HighStockLoan Customer Service: 1566-5113

Go to: https://www.hisl.co.kr


Wonik, Alteogen, Hanwha Ocean, SPG, Samsung Electronics



※ The above content is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing